NCT01745783View on ClinicalTrials.gov

Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

January 31, 2013

Primary Completion Date

June 30, 2020

Study Completion Date

June 30, 2020

Conditions
Multiple Sclerosis
Interventions
OTHER

Bone marrow mesenchymal stem cells autologous

Infusion of mesenchymal cells from autologous bone marrow in a dose of 1-2x106 cells / kg

OTHER

Placebo comparator

Lactated Ringer's solution, 2.5% glucose and 1% human albumin.

Trial Locations (3)

14004

University Hospital Reina Sofia, Córdoba

29010

University Regional Hospital Carlos Haya, Málaga

41009

University Hospital Virgen Macarena, Seville

All Listed Sponsors
collaborator

Iniciativa Andaluza en Terapias Avanzadas

OTHER

lead

Andalusian Initiative for Advanced Therapies - Fundación Pública Andaluza Progreso y Salud

OTHER

NCT01745783 - Mesenchymal Cells From Autologous Bone Marrow, Administered Intravenously in Patients Diagnosed With Multiple Sclerosis | Biotech Hunter | Biotech Hunter